Eli Lilly boosts full-year forecast as weight-loss drug demand surges

Eli Lilly and Company raised its 2025 revenue and adjusted-EPS guidance after third-quarter sales of its weight-loss drug Zepbound reached US$3.6 billion and diabetes drug Mounjaro US$6.5 billion, both above analyst estimates. The company now expects adjusted EPS of US$23.00–23.70 and revenues of US$63–63.5 billion. Despite pressure from U.S. drug-price reform risks, strong growth in its incretin portfolio drove the upgrade and shares jumped more than 5% in pre-market trading.